The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer

International Journal of Oncology

Volumn 35, Issue 2, 2009, Pages 239-248

  Nakamura, Keiichiro ^a   Abarzua, Fernando ^a   Hongo, Atsushi ^a   Kodama, Junichi ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptotic pathway; Cervical cancer; Favorable prognostic marker; Hepatocyte growth factor activator inhibitor 1; Therapeutic target

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; HEPSIN; MAGI 1 PROTEIN; MATRIPTASE; MUGG 1 PROTEIN; PDZ PROTEIN; PROSTASIN; PROTEIN BCL 2; PROTEIN BCL XL; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; LEUKOCYTE ELASTASE INHIBITOR; SPINT1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME; UTERINE CERVIX CANCER; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; UTERINE CERVIX TUMOR;

ADULT; AGED; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; FEMALE; HELA CELLS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 69449086849     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000333     Document Type: Article

References (30)

1. Wang SS and Hildesheim A: Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 31: 35-40, 2003.
2. Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB and Bae DS: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 36: 626-633, 2005.
3. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL and Agus DB: CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 61: 228-235, 2004.
4. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY and Edwards DR: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 92: 2171-2180, 2005.
5. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL and Camp RL: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63: 1101-1105, 2003.
6. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H and Sellar GC: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 8: 1101-1107, 2002.
7. Lee SL, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720-36725, 2000.
8. Moran P, Li W, Fan B, Vij R, Eigenbrot C and Kirchhofer D: Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 281: 30439-30446, 2006.
9. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR and Craik CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333-26342, 2000.
10. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX, Antalis TM, Bugge TH and List K: Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 281: 32941-32945, 2006.
11. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B and Moran P: Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 579: 1945-1950, 2005.
12. Kataoka H, Miyata S, Uchinokura S and Itoh H: Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 22: 223-236, 2003.
13. Fan B, Wu TD, Li W and Kirchhofer D: Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J Biol Chem 280: 34513-34520, 2005.
14. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K and Koono M: Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 275: 40453-40462, 2000.
15. Lin CY, Anders J, Johnson M and Dickson RB: Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 274: 18237-18242, 1999.
16. Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T and Austin RJ: Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 390: 125-136, 2005.
17. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS and Bugge TH: Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 19: 1934-1950, 2005.
18. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF and Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227, 2006.
19. Parr C, Watkins G, Mansel RE and Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10: 202-211, 2004.
20. Zeng L, Cao J and Zhang X: Expression of serine protease SNC19/ matriptase and its inhibitor hepatocyte growth factor activator inhibitor type1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 11: 6202-6207, 2005.
21. Mitsuhashi A, Tanaka H, Tanaka N, Sugita M, Shirasawa H, Tokita H, Eda H and Sekiya S: Establishment and characterization of a new HPV-negative squamous cell carcinoma cell line (Yumoto) from the human uterine cervix. Gynecol Oncol 70: 339-347, 1998.
22. Huibregtse JM, Scheffner M and Howley PM: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13: 4918-4927, 1993.
23. Thomas M, Glaunsinger B, Pim D, Javier R and Banks L: HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 20: 5431-5439, 2001.
24. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L and Banks L: Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 21: 5088-5096, 2002.
25. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E and Howley PM: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8: 4099-4105, 1989.
26. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH and Antalis TM: Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22: 237-258, 2003.
27. Parr C and Jiang WG: Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 119: 1176-1183, 2006.
28. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nuñez G and Castle VP: Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55: 2576-2582, 1995.
29. Farrow SN, White JH, Martinou I, Raven T, Pun KT, Grinham CJ, Martinou JC and Brown R: Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374: 731-733, 1995.
30. Cheng EH, Levine B, Boise LH, Thompson CB and Hardwick JM: Bax-independent inhibition of apoptosis by Bcl-XL. Nature 379: 554-556, 1996.